-
Founded in:
1997-12-10 -
Country:
China -
Address:
No. 111, Yixin Road, Shuangyang Economic Development Zone, Changchun -
Tax NO.:
912201012440638092 -
Registered Funds:
100 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Octreotide acetate |
It can inhibit the pathological excessive secretion of growth hormone, thyroid-stimulating hormone, gastrointestinal and pancreatic endocrine hormones; it can selectively reduce the blood flow and pressure of the portal vein and its collateral circulation, and reduce the pressure of varicose veins in the esophagus and gastric fundus; it can inhibit gallbladder emptying and have a therapeutic effect on pancreatic lesions; it can inhibit the secretion of gastric acid and gastrin, and improve the blood supply to the gastric mucosa; it can inhibit gastrointestinal motility.
More
It can inhibit the pathological excessive secretion of growth hormone, thyroid-stimulating hormone, gastrointestinal and pancreatic endocrine hormones; it can selectively reduce the blood flow and pressure of the portal vein and its collateral circulation, and reduce the pressure of varicose veins in the esophagus and gastric fundus; it can inhibit gallbladder emptying and have a therapeutic effect on pancreatic lesions; it can inhibit the secretion of gastric acid and gastrin, and improve the blood supply to the gastric mucosa; it can inhibit gastrointestinal motility. |
83150-76-9 | 44 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Octreotide acetate |
It can inhibit the pathological excessive secretion of growth hormone, thyroid-stimulating hormone, gastrointestinal and pancreatic endocrine hormones; it can selectively reduce the blood flow and pressure of the portal vein and its collateral circulation, and reduce the pressure of varicose veins in the esophagus and gastric fundus; it can inhibit gallbladder emptying and have a therapeutic effect on pancreatic lesions; it can inhibit the secretion of gastric acid and gastrin, and improve the blood supply to the gastric mucosa; it can inhibit gastrointestinal motility.
More
It can inhibit the pathological excessive secretion of growth hormone, thyroid-stimulating hormone, gastrointestinal and pancreatic endocrine hormones; it can selectively reduce the blood flow and pressure of the portal vein and its collateral circulation, and reduce the pressure of varicose veins in the esophagus and gastric fundus; it can inhibit gallbladder emptying and have a therapeutic effect on pancreatic lesions; it can inhibit the secretion of gastric acid and gastrin, and improve the blood supply to the gastric mucosa; it can inhibit gastrointestinal motility. |
83150-76-9 | 44 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ginsenoside Rg1 |
Enhance the body's stress resistance, adjust endocrine or autonomic nervous system disorders, resist fatigue, and enhance myocardial contractility and increase cardiac output
More
Enhance the body's stress resistance, adjust endocrine or autonomic nervous system disorders, resist fatigue, and enhance myocardial contractility and increase cardiac output |
22427-39-0 | 0 | |
| Re-ChIP-IT |
Enhance the body's stress resistance, adjust endocrine or autonomic nervous system disorders, resist fatigue, and enhance myocardial contractility and increase cardiac output
More
Enhance the body's stress resistance, adjust endocrine or autonomic nervous system disorders, resist fatigue, and enhance myocardial contractility and increase cardiac output |
0 | ||
| Rc |
Enhance the body's stress resistance, adjust endocrine or autonomic nervous system disorders, resist fatigue, and enhance myocardial contractility and increase cardiac output
More
Enhance the body's stress resistance, adjust endocrine or autonomic nervous system disorders, resist fatigue, and enhance myocardial contractility and increase cardiac output |
0 | ||
| Rb2 |
Enhance the body's stress resistance, adjust endocrine or autonomic nervous system disorders, resist fatigue, and enhance myocardial contractility and increase cardiac output
More
Enhance the body's stress resistance, adjust endocrine or autonomic nervous system disorders, resist fatigue, and enhance myocardial contractility and increase cardiac output |
0 | ||
| Rd |
Enhance the body's stress resistance, adjust endocrine or autonomic nervous system disorders, resist fatigue, and enhance myocardial contractility and increase cardiac output
More
Enhance the body's stress resistance, adjust endocrine or autonomic nervous system disorders, resist fatigue, and enhance myocardial contractility and increase cardiac output |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Octreotide acetate |
It can inhibit the pathological excessive secretion of growth hormone, thyroid-stimulating hormone, gastrointestinal and pancreatic endocrine hormones; it can selectively reduce the blood flow and pressure of the portal vein and its collateral circulation, and reduce the pressure of varicose veins in the esophagus and gastric fundus; it can inhibit gallbladder emptying and have a therapeutic effect on pancreatic lesions; it can inhibit the secretion of gastric acid and gastrin, and improve the blood supply to the gastric mucosa; it can inhibit gastrointestinal motility.
More
It can inhibit the pathological excessive secretion of growth hormone, thyroid-stimulating hormone, gastrointestinal and pancreatic endocrine hormones; it can selectively reduce the blood flow and pressure of the portal vein and its collateral circulation, and reduce the pressure of varicose veins in the esophagus and gastric fundus; it can inhibit gallbladder emptying and have a therapeutic effect on pancreatic lesions; it can inhibit the secretion of gastric acid and gastrin, and improve the blood supply to the gastric mucosa; it can inhibit gastrointestinal motility. |
83150-76-9 | 44 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| SodiuM DeMethylcantharidate |
In vitro tests of this product have a destructive or inhibitory effect on the morphology or proliferation of cell lines such as liver cancer, esophageal cancer, laryngeal cancer, lung cancer, and cervical cancer. In vivo tests have a certain inhibitory effect on mouse Ehrlich ascites carcinoma, sarcoma-180 and solid liver cancer. It can increase the respiratory control rate and lysosomal enzyme activity of mitochondria in H22 mouse ascites liver cancer cells, interfere with cancer cell division, block in the M phase, and affect its cycle speed. This product can destroy the skeleton of cancer cells (microfilaments, microtubules), affect the ultrastructure of cancer cells, and cause damage to mitochondria, microvilli and plasma membranes. It can inhibit DNA synthesis of cancer cells, but it does not inhibit normal bone marrow cells, and can increase white blood cells.
More
In vitro tests of this product have a destructive or inhibitory effect on the morphology or proliferation of cell lines such as liver cancer, esophageal cancer, laryngeal cancer, lung cancer, and cervical cancer. In vivo tests have a certain inhibitory effect on mouse Ehrlich ascites carcinoma, sarcoma-180 and solid liver cancer. It can increase the respiratory control rate and lysosomal enzyme activity of mitochondria in H22 mouse ascites liver cancer cells, interfere with cancer cell division, block in the M phase, and affect its cycle speed. This product can destroy the skeleton of cancer cells (microfilaments, microtubules), affect the ultrastructure of cancer cells, and cause damage to mitochondria, microvilli and plasma membranes. It can inhibit DNA synthesis of cancer cells, but it does not inhibit normal bone marrow cells, and can increase white blood cells. |
13114-29-9 | 0 |